Read Gene SA
WSE:RDG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Read Gene SA
WSE:RDG
|
PL |
|
T
|
Thaitheparos PCL
SET:SAUCE
|
TH |
|
Ascelia Pharma AB
F:7ZA
|
SE |
|
Anglo Australian Resources NL
ASX:AAR
|
AU |
Intrinsic Value
Is RDG undervalued or overvalued?
See the intrinsic value estimate for Read Gene SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
RDG looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with RDG’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Read Gene Does
Read-Gene SA engages in the medical research and testing. The company is headquartered in Szczecin, Woj. Zachodniopomorskie. The company went IPO on 2009-02-12. The company is focused on technologies which aim is to detect, prevent and treat malignant tumors. The firm specializes in three fields: chemoprevention, clinical trials and genetic testing. The company offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements.
- Headquarters
- Poland PL
- IPO date
- Feb 12, 2009
Revenue & Expenses Breakdown
Read Gene SA
Earnings Waterfall
Read Gene SA
The intrinsic value for Read Gene SA (RDG) under the Base Case is hidden PLN.
Compared with the current market price of 4.84 PLN, the stock appears hidden.